Recent studies have suggested that P2Y12 inhibitors, primarily used as antiplatelet drugs in cardiovascular diseases, may have potential as an adjunct therapy for infections owing to their anti-inflammatory and immunomodulatory effects [3,4]. This evidence concerns the gene P2RY12 and cardiovascular disorder.